Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088904814> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W3088904814 endingPage "S716" @default.
- W3088904814 startingPage "S715" @default.
- W3088904814 abstract "Immune checkpoint inhibitors (ICI) have improved patient outcomes in a variety of cancers but with variable efficacy. In the past 24 months, several observational studies, mostly retrospective, suggested that antibiotic (ABX) use may be associated with a lowered efficacy of ICI and survival of patients. ABX-induced disruption of the gut microbiota and the complex interplay between the immune system and the microbiota have been advanced as the likely mechanisms underlying the observed effect. We aim at reviewing the meta-analyses that summarized the findings reported in literature. We systematically searched Medline, the Cochrane Library, and oncology conferences proceedings to identify the systematic reviews and meta-analyses as well as all the recent studies that were not included in them. We identified 4 meta-analyses published since 2019 studying the overall survival (OS) and progression-free survival (PFS) of cancer patients treated with ICI (mainly anti-PD(L)1 antibodies as monotherapy or combined with anticancer drugs) and ABX. In all, ABX use is reported to have a negative impact on the survival of patients treated with ICI regardless of cancer type. The pooled hazard ratio (HR) ranged from 1.47 to 1.84 for PFS and 1.69 to 2.37 for OS, revealing a significantly reduced survival in patients with cancer exposed to ABX. In all meta-analyses, the use of ABX around the ICI treatment start appeared to be most detrimental to the outcomes.Table: 1043P1st AuthorHuangWilsonLurienneXuCancerNon-small-cell lung cancer (NSCLC), Melanoma, Renal cell carcinoma (RCC), Urothelial Carcinoma (UC), MixedNSCLC, Melanoma, RCC, UC, MixedNSCLCNSCLC, Melanoma, RCC, MixedHR OS [95% CI]2.37 [2.05; 2.75]1.92 [1.37; 2.68]1.69 [1.25; 2.29]1.90 [1.55; 2.34]HR PFS [95% CI]1.84 [1.49; 2.26]1.65 [1.30; 2.10]1.47 [1.13; 1.90]1.53 [1.30; 1.79] Open table in a new tab The independently-developed meta-analyses vary in the scope of studies included and their methodology but they commonly conclude on a significant deleterious effect of ABX use on the survival of patients treated with ICI. The topic deserves further research to understand the mechanisms at stake and improve care of patients." @default.
- W3088904814 created "2020-10-01" @default.
- W3088904814 creator A5029510428 @default.
- W3088904814 creator A5034145747 @default.
- W3088904814 creator A5040199640 @default.
- W3088904814 creator A5040297191 @default.
- W3088904814 creator A5050796727 @default.
- W3088904814 creator A5051690651 @default.
- W3088904814 date "2020-09-01" @default.
- W3088904814 modified "2023-10-01" @default.
- W3088904814 title "1043P A review of meta-analyses on the impact of antibiotics on the efficacy of immune checkpoint inhibitors and cancer patients’ survival" @default.
- W3088904814 doi "https://doi.org/10.1016/j.annonc.2020.08.1163" @default.
- W3088904814 hasPublicationYear "2020" @default.
- W3088904814 type Work @default.
- W3088904814 sameAs 3088904814 @default.
- W3088904814 citedByCount "0" @default.
- W3088904814 crossrefType "journal-article" @default.
- W3088904814 hasAuthorship W3088904814A5029510428 @default.
- W3088904814 hasAuthorship W3088904814A5034145747 @default.
- W3088904814 hasAuthorship W3088904814A5040199640 @default.
- W3088904814 hasAuthorship W3088904814A5040297191 @default.
- W3088904814 hasAuthorship W3088904814A5050796727 @default.
- W3088904814 hasAuthorship W3088904814A5051690651 @default.
- W3088904814 hasBestOaLocation W30889048141 @default.
- W3088904814 hasConcept C105795698 @default.
- W3088904814 hasConcept C121608353 @default.
- W3088904814 hasConcept C126322002 @default.
- W3088904814 hasConcept C143998085 @default.
- W3088904814 hasConcept C207103383 @default.
- W3088904814 hasConcept C2776478404 @default.
- W3088904814 hasConcept C2777472916 @default.
- W3088904814 hasConcept C2777701055 @default.
- W3088904814 hasConcept C2780030458 @default.
- W3088904814 hasConcept C33923547 @default.
- W3088904814 hasConcept C44249647 @default.
- W3088904814 hasConcept C60962613 @default.
- W3088904814 hasConcept C71924100 @default.
- W3088904814 hasConcept C95190672 @default.
- W3088904814 hasConceptScore W3088904814C105795698 @default.
- W3088904814 hasConceptScore W3088904814C121608353 @default.
- W3088904814 hasConceptScore W3088904814C126322002 @default.
- W3088904814 hasConceptScore W3088904814C143998085 @default.
- W3088904814 hasConceptScore W3088904814C207103383 @default.
- W3088904814 hasConceptScore W3088904814C2776478404 @default.
- W3088904814 hasConceptScore W3088904814C2777472916 @default.
- W3088904814 hasConceptScore W3088904814C2777701055 @default.
- W3088904814 hasConceptScore W3088904814C2780030458 @default.
- W3088904814 hasConceptScore W3088904814C33923547 @default.
- W3088904814 hasConceptScore W3088904814C44249647 @default.
- W3088904814 hasConceptScore W3088904814C60962613 @default.
- W3088904814 hasConceptScore W3088904814C71924100 @default.
- W3088904814 hasConceptScore W3088904814C95190672 @default.
- W3088904814 hasLocation W30889048141 @default.
- W3088904814 hasOpenAccess W3088904814 @default.
- W3088904814 hasPrimaryLocation W30889048141 @default.
- W3088904814 hasRelatedWork W2039727033 @default.
- W3088904814 hasRelatedWork W2581928246 @default.
- W3088904814 hasRelatedWork W2623600402 @default.
- W3088904814 hasRelatedWork W2734975679 @default.
- W3088904814 hasRelatedWork W2784136589 @default.
- W3088904814 hasRelatedWork W2799310318 @default.
- W3088904814 hasRelatedWork W3013588444 @default.
- W3088904814 hasRelatedWork W3024842894 @default.
- W3088904814 hasRelatedWork W3157589766 @default.
- W3088904814 hasRelatedWork W4377100578 @default.
- W3088904814 hasVolume "31" @default.
- W3088904814 isParatext "false" @default.
- W3088904814 isRetracted "false" @default.
- W3088904814 magId "3088904814" @default.
- W3088904814 workType "article" @default.